Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer.
作者信息
Nagano Tatsuya, Tachihara Motoko, Hazama Daisuke, Nishimura Yoshihiro
机构信息
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
出版信息
J Thorac Dis. 2020 Aug;12(8):4561-4563. doi: 10.21037/jtd.2020.04.34.
Abstract
摘要
相似文献
1
Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer.转化医学学会共识（2019年版）展示了表皮生长因子受体（EGFR）突变型肺癌术后管理的一种选择。
J Thorac Dis. 2020 Aug;12(8):4561-4563. doi: 10.21037/jtd.2020.04.34.
2
Erratum to Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).《转化医学学会关于EGFR突变型肺癌术后管理的共识（2019年版）》勘误
Transl Lung Cancer Res. 2020 Jun;9(3):944. doi: 10.21037/tlcr.2020.03.39.
3
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
4
One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer.在正确方向上迈出的一小步：转化医学学会2019年关于表皮生长因子受体突变型肺癌术后管理的共识
J Thorac Dis. 2020 Sep;12(9):5046-5049. doi: 10.21037/jtd-2020-51.
5
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.国际肺癌研究协会关于优化 EGFR 突变阳性非小细胞肺癌管理的共识声明：2016 年现状。
J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23.
6
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.厄洛替尼对比全脑放疗用于表皮生长因子受体突变型非小细胞肺癌伴多发脑转移患者（BRAIN）：一项多中心、三期、开放标签、平行、随机对照临床试验。
Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.
7
Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.根据国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新的肺腺癌分类，EGFR突变状态与腺癌主要组织学亚型的相关性。
Arch Pathol Lab Med. 2014 Oct;138(10):1353-7. doi: 10.5858/arpa.2013-0376-OA. Epub 2014 Feb 26.
8
Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?在晚期肺鳞状细胞癌中是否应该检测表皮生长因子受体（EGFR）突变以指导一线治疗？
Cancer Chemother Pharmacol. 2014 Oct;74(4):661-5. doi: 10.1007/s00280-014-2536-3. Epub 2014 Jul 23.
9
Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.韩国妇科肿瘤学会卵巢癌管理实践指南：韩国共识声明。
J Gynecol Oncol. 2018 Jul;29(4):e56. doi: 10.3802/jgo.2018.29.e56. Epub 2018 Mar 10.
10
Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.西妥昔单抗修饰的介孔二氧化硅纳米药物特异性靶向表皮生长因子受体（EGFR）突变的肺癌并克服耐药性。
Sci Rep. 2016 May 6;6:25468. doi: 10.1038/srep25468.
本文引用的文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
2
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.吉非替尼单药对比吉非替尼联合化疗用于表皮生长因子受体突变的非小细胞肺癌：NEJ009 研究。
J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4.
3
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
4
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.ADAURA：奥希替尼对比安慰剂用于完全手术切除后的 EGFR 突变阳性早期 NSCLC 患者的 III 期、双盲、随机研究。
Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1.
5
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
6
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
7
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.非小细胞肺癌患者中表皮生长因子受体（EGFR）突变的患病率：一项系统评价和荟萃分析。
Oncotarget. 2016 Nov 29;7(48):78985-78993. doi: 10.18632/oncotarget.12587.
8
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.厄洛替尼辅助治疗与安慰剂对照用于 IB 期-IIIA 期非小细胞肺癌患者（RADIANT）：一项随机、双盲、III 期临床试验。
J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.
9
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.吉非替尼对比安慰剂用于完全切除的非小细胞肺癌：NCIC CTG BR19 研究结果。
J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26.
10
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.吉非替尼用于辅助治疗：一项针对完全切除的非小细胞肺癌患者的III期研究的安全性结果
Anticancer Drugs. 2005 Nov;16(10):1123-8. doi: 10.1097/00001813-200511000-00012.
Zotero 插件